Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOW-OGESTREL-28 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: ethinyl estradiol and norgestrel inhibit ovulation via suppression of gonadotropins (LH, FSH); increase viscosity of cervical mucus, impairing sperm penetration; alter endometrial structure, reducing implantation likelihood.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy,Oral contraception
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 28 days, with 21 active tablets followed by 7 inactive tablets.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Norgestrel: ~45 hours (terminal). Ethinyl estradiol: ~13 hours (terminal). Steady-state achieved within 5-7 days.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol: metabolized via CYP3A4, undergoes first-pass metabolism, conjugates with sulfate and glucuronide. Norgestrel: primarily metabolized via reduction, hydroxylation, and conjugation; CYP3A4 involved.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal 50-60% as metabolites, fecal 40-50% via biliary elimination. Ethinyl estradiol undergoes enterohepatic recirculation.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Norgestrel: 97-99% bound to SHBG and albumin. Ethinyl estradiol: 98% bound to albumin.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Norgestrel: 3-4 L/kg (extensive tissue distribution). Ethinyl estradiol: 3-5 L/kg.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Norgestrel: ~90% oral (first-pass metabolism minimal). Ethinyl estradiol: ~45% oral (extensive first-pass metabolism).
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dosage adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (Cr Cl <30 m L/min); use with caution.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in severe hepatic disease or liver tumors (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment established.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not indicated for premenarchal patients. Postmenarchal adolescents: same as adult dose (one tablet daily) after menarche.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for postmenopausal women due to lack of contraceptive need and potential increased risks of thrombosis, cardiovascular events, and malignancies.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day) and is significant in women over 35. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Thrombotic events (e.g., DVT, PE, stroke, MI); hepatic neoplasia; elevated blood pressure; gallbladder disease; carbohydrate and lipid metabolism effects; headache; uterine bleeding irregularities; ectopic pregnancy risk; reduced efficacy with hepatic impairment; monitoring for hypertension, hyperlipidemia, and glucose intolerance.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thrombophlebitis or thromboembolic disorders; history of DVT or PE; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; endometrial carcinoma or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels due to CYP3A4 inhibition, but clinical significance is minimal. Maintain consistent dietary habits regarding grapefruit consumption to avoid fluctuation in drug levels. Alcohol does not directly affect efficacy but may impair judgment regarding compliance.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
First trimester: Low risk of major malformations; no evidence of increased risk of neural tube defects. Second and third trimesters: Possible increased risk of liver tumors and jaundice; may cause fetal harm if administered during pregnancy due to hormonal effects. Post-marketing reports of external genitalia anomalies in male and female fetuses exposed to progestins. Not recommended for use during pregnancy. Discontinue if pregnancy occurs.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Excreted in breast milk in small amounts; estimated M/P ratio approximately 0.5-0.8 for progestins. May reduce milk production and quality. Use with caution and only if clearly needed. Monitor infant for jaundice, weight gain, and hormonal effects.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dose adjustments recommended in pregnancy as drug is contraindicated. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may reduce efficacy if used inadvertently; discontinue immediately upon recognition of pregnancy.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
Low-Ogestrel-28 (norgestrel/ethinyl estradiol) is a monophasic oral contraceptive. Take at the same time daily to maintain hormone levels. Missed pill management: if one pill is missed, take it as soon as remembered; if two or more pills are missed, use backup contraception for 7 days. Consider potential drug interactions with CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) which may reduce efficacy. Breakthrough bleeding is common in first 3 months; if persistent, rule out pregnancy or cervical pathology. Do not use in patients with history of thromboembolic disease, migraines with aura, or smokers >35 years old.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one pill daily at the same time, even if you do not have intercourse.,If you miss a pill, refer to the packaging instructions or contact your healthcare provider.,Use a backup method (e.g., condoms) during the first week and if doses are missed.,Common side effects include nausea, breast tenderness, breakthrough bleeding, and mood changes; these often improve after 3 months.,Serious risks include blood clots, stroke, and liver tumors; seek medical help for leg pain, chest pain, severe headache, or vision changes.,Do not smoke while taking this medication, especially if over 35 years old.,Inform all healthcare providers that you are taking this contraceptive.,This medication does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOW-OGESTREL-28 vs ALTAVERA, answered by our medical review team.
LOW-OGESTREL-28 is a Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol and norgestrel inhibit ovulation via suppression of gonadotropins (LH, FSH); increase viscosity of cervical mucus, impairing sperm penetration; alter endometrial structure, reducing implantation likelihood.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOW-OGESTREL-28 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOW-OGESTREL-28 is: One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 28 days, with 21 active tablets followed by 7 inactive tablets.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOW-OGESTREL-28 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOW-OGESTREL-28 is classified as Category C. First trimester: Low risk of major malformations; no evidence of increased risk of neural tube defects. Second and third trimesters: Possible increased risk of liver tumors and jau. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.